Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDO-05 is a preclinical small interfering RNA (siRNA) therapeutic candidate being developed by Sirius Therapeutics (also known as Sirius Natural) for the treatment of muscle wasting. As part of the company's cardiometabolic and obesity-focused pipeline, SRNDO-05 utilizes proprietary delivery technology designed to target specific tissues such as the liver, adipose tissue, heart, kidney, or the central nervous system (CNS). The specific molecular target of the siRNA is currently undisclosed by the developer. The program is positioned within the obesity therapeutic area of the company's pipeline and is currently in the Pre-Clinical/IND-enabling stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SRNDO-05.